Navigation Links
Group Therapy: New approach to psychosis treatment could target multiple nervous system receptors
Date:2/1/2013

Philadelphia, Pa. Antipsychotic drugs, used in the treatment of psychotic disorders involving severe delusions and hallucinations, have been studied for more than 70 years. Currently available antipsychotic drugs, however, only alleviate certain symptoms, with results that vary greatly from patient to patient and frequently cause significant side effects.

A new understanding of how the brain's G-protein receptors work may soon enable a way to better customize and target antipsychotic drugs to treat specific symptoms. Researchers from Virginia Commonwealth University (VCU) will present their findings at the 57th Annual Meeting of the Biophysical Society (BPS), held Feb. 2-6, 2013, in Philadelphia, Pa.

G-protein coupled receptors (GPCRs) are responsible for activating so-called "G-proteins," internal signaling messengers that control the activity of many other internal proteins. The starring role of GPCRs in regulating a cell's activity makes them a leading pharmaceutical target: approximately 50 percent of the antipsychotic drugs produced are aimed at these important nervous system receptors.

A specific GPCR is integral to each of three key pathways for intercellular signaling, one for each of the chemical messengers dopamine, serotonin, and glutamate. But these individual GPCRs also form complexes with each other, altering their effects on signaling in the brain. The VCU team has focused on how GPCR complexes influence signaling in a distinct way from how individual GPCRs operate.

"The realization that receptors in the brain that bind and interpret dopamine, serotonin, and glutamate neurotransmitters form complexes with one another that signal very differently than when these receptors are found in isolation, promises to change the way we approach treatment of psychosis," explains VCU Ph.D. candidate Jason Younkin, who will present the team's findings.

Instead of targeting one neurotransmitter pathway at a time, Younkin and colleagues plan to target two or more at the same time. Antipsychotic drugs that target the complexes formed by the individual GPCRs will allow use of the signaling differences and could lead to more effective therapies.

"By understanding how receptor complexes signal and learning how to control these signals, it should enable the development of specific antipsychotic drugs that lack the many side effects that exist today," says VCU professor Diomedes E. Logothetis, a co-author of the study.


'/>"/>

Contact: Ellen R. Weiss
eweiss@biophysics.org
240-290-5606
American Institute of Physics
Source:Eurekalert

Related medicine news :

1. Fish Like Grouper, Barracuda May Pose Food-Poisoning Risk
2. The US Drug Watchdog Now Urges Young Women Who Suffered a Heart Attack or Blood Clotting After Taking Yaz or Yasmin Birth Control Pills to Contact the Johnson Law Group
3. US Drug Watchdog Now Urges Family Members Of Diabetics Who Used the Diabetes Drug Actos and Then Were Diagnosed with Bladder Cancer to Call The Johnson Law Group ASAP
4. Cunningham Financial Group Encourages Women to Celebrate “Cervical Health Awareness Month” by Following Important Health Tips
5. US Drug Watchdog is Now Urging Bladder Cancer Victims to Call the Johnson Law Group if They Used Diabetes Drug Called Actos Prior to Diagnosis
6. Dr. Andy Chiou elected President and Chief Executive Officer of Peoria Surgical Group, Ltd.
7. Ob/Gyn Group Urges Docs to Help Prevent Octomom-Type Multiple Births
8. The Boston Eye Group Implants First Intraocular Pressure Transducer for Glaucoma Monitoring
9. US Drug Watchdog Now Urges Users of Yaz Yasmin Birth Control Pills That Had a Stroke Or Developed Other Serious Medical Conditions to Contact The Johnson Law Group
10. Acceleration Fitness Center Now Offering Group Training Programs for Middle and High School Athletes
11. US Drug Watchdog Now Urges Families Of Diabetics Who Used The Diabetes Drug Actos, Developed Bladder Cancer and Died To Call The Johnson Law Group-For A Legal Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
Breaking Medicine Technology: